Patents by Inventor Per Axel Björk

Per Axel Björk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunomodulating compounds
    Patent number: 6642249
    Abstract: The present invention relates to a novel heterocyclic compound, a pharmaceutical composition comprisining said compound, a method and use of said compound for clinical treatment of medical conditions which may benefit from immunomodulation, e.g. rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28. A method of screening compounds for their ability of inhibiting ligand-induced co-stimulatory receptor internalization pathways in immune competent human cells is described. Said immune competent human cells are incubated at conditions capable of inducing co-stimulatory receptor internalization in the presence of at least one test compound and the suppression of the ligand-induced co-stimulatory receptor internalization determined.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: November 4, 2003
    Assignee: Active Biotech AB
    Inventors: Per Axel Björk, Tomas Fex, Lars Olof Göran Pettersson, Pous Sørensen, Dorthe Da Graça Thrige
  • Novel immunomodulating compounds
    Publication number: 20030022913
    Abstract: The present invention relates to a novel heterocyclic compound, a pharmaceutical composition comprisining said compound, a method and use of said compound for clinical treatment of medical conditions which may benefit from immunomodulation, e.g. rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.
    Type: Application
    Filed: June 26, 2002
    Publication date: January 30, 2003
    Inventors: Per Axel Bjork, Tomas Fex, Lars Olof Goran Pettersson, Poul Sorensen, Dorthe Da Graca Thrige